The cancer process and pathophysiology of colorectal cancer : general concepts by Gałaś, Aleksander
3. the CanCer ProCeSS anD PathoPhySiology 
of ColoreCtal CanCer: general ConCePtS
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Cancers	arise	as	a	result	of	a	multistep	process	involving	multiple	mutations	in	different	
genes.	Cancer	develops	as	a	result	of	interaction	between	genetic	susceptibility	and	pro-
tective	or	promoting	role	of	environmental	factors,	such	as	diet	and	lifestyle.
The	genetic	changes,	which	may	lead	to	clinical	colorectal	cancer,	have	been	inten-
sively	investigated	for	the	last	thirty	years.	It	has	been	noticed	that	colon	cancer	is	usu-
ally	observed	in	one	of	three	major	patterns:	sporadic,	inherited	or	familial.
The	most	frequent,	sporadic,	accounts	for	about	70%	of	colorectal	cancer	cases	in	the	
population.	Sporadic	colorectal	cancer	occurs	 in	persons	without	familial	or	 inherited	
predisposition	usually	over	50	years	of	age.	It	is	attributed	to	dietary	and	environmental	
factors	cumulated	with	the	age.
Inherited	 colorectal	 cancer	 covers	 two	main	 groups	 of	 cancers:	with	 and	without	
polyps,	which	are	(or	not)	major	manifestations	of	the	disease.	The	polyposis	syndromes	
are	divided	into	familial	adenomatous	polyposis	and	the	hamartomatous	polyposis	syn-
dromes.	The	non-polyposis	 predominant	 syndromes	 include	 hereditary	 non-polyposis	
colorectal	cancer	(HNPCC)	(Lynch	syndrome	I)	and	the	cancer	family	syndrome	(Lynch	
syndrome	II).
Familial	colon	cancer	is	recognised	when	colon	cancer	develops	too	frequently	to	be	
considered	sporadic,	but	not	in	a	pattern	characteristic	for	inherited	syndrome	(1).
The	hereditary	cancer	is	a	result	of	the	mutations	presented	in	the	parent	cells	and	is	
transmitted	from	the	mother	or	father	as	inherited	defect.
More	common,	sporadic	colorectal	cancer	develops	as	a	result	of	spontaneous	muta-
tion	occurring	in	a	somatic	cell(s)	during	the	growth	and	development.	If	the	mutation	
results	 in	uncontrolled	proliferation,	 the	development	of	cancer	 is	observed.	Sporadic	
colorectal	cancer	occurs	when	accumulation	of	multiple	mutations	is	present	(2).	
the natural history of colorectal cancer 
Data	from	clinical	and	pathological	studies	showed	that	most	human	colorectal	cancers	
arise	from	adenomas	(3,	4).	However,	small	part	of	adenomas	progresses	 into	cancer.	
Only	about	10%	of	all	of	adenomas,	at	least	1	cm	in	diameter,	develop	into	cancer	during	
the	following	10	years	(5).	It	is	not	clear	how	much	time	takes	progression	from	normal	
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mucosa	to	polyp.	Typically,	sporadic	colon	cancer	appears	at	older	age.	It	suggests	that	
it	needs	more	than	10–20	years	for	the	development	of	the	polyp,	but	there	are	some	he-
reditary	colorectal	cancers	that	typically	appear	at	second	or	third	decade	of	life.	In	this	
case,	the	progression	is	much	more	rapid.
To	develop	cancer,	three	main	types	of	genes	are	usually	mutated:	oncogenes,	tumour	
suppressor	genes,	and	mismatch	repair	genes.	Oncogenes	are	normal	genes	responsible	
for	the	stimulation	of	controlled	cellular	proliferation	(6).	The	mutation	of	these	genes	
leads	to	uncontrolled	cellular	proliferation.	Tumour	suppressor	genes	(antioncogenes)	are	
responsible	for	inhibition	of	cell	cycle	and	promotion	of	apoptosis.	If	the	function	of	the	
latter	two	is	disturbed,	the	uncontrolled	proliferation	follows.	However,	one	functioning	
allele	of	these	genes	is	enough	to	control	the	cell	cycle	(7).	Mismatch	repair	genes	are	
genes	 coding	 enzymes	 responsible	 for	monitoring	 newly	 formed	DNA	and	 correcting	
replication	errors	(8).	Defective	MMR	genes	are	associated	with	phenotype	called	muta-
tor	phenotype.	The	accumulation	of	replication	errors	throughout	genome	increases	the	
probability	of	the	mutation	in	important	regulatory	genes	and	may	lead	to	cancer	(9).	
the genetics of hereditary colorectal cancers
The	 hereditary	 colorectal	 cancers	 are	 familial	 adenomatous	 polyposis	 and	 hereditary	
non-polyposis	colorectal	cancers	(HNPCC).
Familial	adenomatous	polyposis	is	an	autosomal	dominantly	inherited	disease,	which	
occurs	 in	1	per	7000	 individuals.	The	penetrance	of	 the	disease	 is	almost	100%.	The	
disease	develops	most	frequently	in	the	second	or	third	decade	of	life,	presenting	with	
a	number	of	polyps	throughout	the	whole	large	bowel.
Molecular	studies	on	familial	adenomatous	polyposis	(FAP)	originally	suggested	that	
the	germline	mutation	responsible	for	the	disease	is	the	mutation	in	the	tumour	suppres-
sor	gene,	adenomatous	polyposis	coli	(APC),	localised	on	chromosome	5q	(10).	Howev-
er,	later	observations	showed	that	up	to	30%	of	patients	with	the	diagnosis	of	FAP	might	
show	no	APC	mutations	(11).	It	has	been	suggested	that	in	those	patients	the	presence	of	
bi-allelic	mutation	of	the	MYC	gene	is	responsible	for	the	development	of	FAP	(12).
Hereditary	non-polyposis	colorectal	cancer	is	also	autosomal	dominant	disease.	Typi-
cally,	it	appears	at	early	age	and	predominantly	affects	proximal	colon.	HNPCC	tumours	
have typical pathologic features like lymphocytic infiltration, high mucinous content and 
poor	differentiation.	Clinically,	HNPCC	is	divided	into	Lynch	I	and	Lynch	II	syndrome.	
Lynch	I	syndrome	is	characterised	by	the	changes	observed	only	in	the	colon	and	Lynch	
II	syndrome	is	diagnosed	when	other,	extracolonic	localizations,	like	endometrial,	ovar-
ian,	urinary,	pancreatic,	gastric,	small	bowel	or	brain	cancer(s)	are	observed	(13).	The	
penetrance	of	the	HNPCC	is	about	80%.
The	genome	analysis	of	the	HNPCC	patients	showed	that	most	of	these	cancers	pre-
sented	short	repetitive	DNA	sequences,	the	so	called	microsatellites	(14).	The	disease	
was	 attributed	 to	 the	mutations	 in	DNA	mismatch	 repair	 (MMR)	 genes,	hMLHl and 
hMSH2 (15).	There	were	also	discovered	additional	genes	responsible	for	the	develop-
ment	of	HNPCC,	i.e.,	hPMS1,	hPMS2,	hMLH3,	hMSH3,	hMSH6,	and	EXO1	 (16,	17,	
18).	The	most	common	genes	observed	among	patients	with	HNPCC	are	hMLH1 and	
hMSH2.	Mutations	of	these	two	genes	are	observed	in	about	90%	known	mutations	in	
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HNPCC.	The	mutations	of	MMR	lead	to	accumulations	of	replication	errors	and	micro-
satellite	instability	(MSI)	phenotype	(19).	High	level	of	MSI	(MSI-H)	is	observed	typi-
cally	when	mutations	in	hMLH1 and	hMSH2	are	both	present.
the genetics of sporadic colorectal cancer
The genetic changes, which may lead to sporadic colorectal cancer were first described 
by	Fearon	 and	Vogelstein	 (2)	 as	 the	multistep	 process	 that	might	 be	 observed	 in	 the	
pathway	from	the	healthy	tissue	to	the	cancerous	tissue	(Fig.	3.1).	It	was	suggested	that	
colorectal	cancer	tumours	develop	as	a	result	of	the	accumulation	of	activated	oncogenes	
and	inactivated	tumour	suppressor	genes.
The first noticed mutation in the pathway is the mutation in the tumour suppressor 
gene	APC	that	was	observed	in	50%	of	cancer	cases	and	in	about	30%	of	adenomas.	It	
was	suggested	that	the	gene	might	be	responsible	for	the	initiation	of	the	process.	The	
APC	gene	is	thought	to	modulate	the	beta-catenin	protein,	which	regulates	cell	signal	
Figure 3.1. Multistep process of tumorigenesis in the “suppressor” pathway
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transduction	and	growth	(20).	APC	mutations	play	key	role	in	early	cell	transformation,	
and	thus,	the	APC	gene	is	sometimes	called	“gatekeeper”	gene	(21).
The	oncogene	k-ras	is	another	gene	involved	in	the	carcinogenesis	of	colorectal	can-
cer.	The	gene	codes	for	the	binding	protein	that	acts	as	one-way	switch	for	extracellular	
growth	signals.	Improper	activation	of	k-ras	leads	to	change	of	related	protein	that	re-
sults	in	continuous	stimulation	of	the	cell	to	grow.	Mutations	of	k-ras	are	detected	in	up	
to	50%	of	cases	of	sporadic	colorectal	cancer.
Another	gene	responsible	for	colorectal	cancer	is	the	DCC	(deleted	in	colorectal	ad-
enoma)	(22).	The	DCC is	localized	on	18q	and	it	encodes	a	protein	that	plays	role	in	cell	
to	cell	interactions.	Though	deletions	of	DCC	were	found	in	over	70%	of	tumours,	inac-
tivating	mutations	were	not	found	in	the	residual	DCC	allele	(4).	Moreover,	some	inves-
tigators	discovered	other	deleted	genes	on	the	chromosome	18q,	SMAD-2 and SMAD-4,	
and	these	genes	seem	to	have	clearer	characteristic	of	tumour	suppressors	(23).
The	next	gene	in	the	pathway	is	p53.	It	is	tumour	suppressor	gene	responsible	for	the	
arrest	of	cell	cycle	in	the	G1	stage	to	facilitate	repair	of	DNA	and	to	induce	apoptosis,	if	
required.	Hence,	it	is	sometimes	called	“guardian	of	the	genome.”	The	inactivation	of	the	
p53	is	observed	in	about	75%	of	sporadic	colorectal	cancers.
There	is	an	agreement,	however,	that	not	appropriate	chronological	order	of	appear-
ance,	but	accumulation	of	changes	 is	 responsible	 for	 the	development	of	 tumour.	Tu-
mours	evolving	through	inactivating	mutations	of	tumour	suppressor	genes	and	accom-
panying	mutations	of	oncogenes	or	losses	of	adequate	alleles	(originally	termed	“loss	of	
heterozygosity”	(LOH)	due	to	chromosomal	losses	observed	on	chromosomes	5q,	17p	
and	18q	among	patients	with	sporadic	colorectal	cancer	(2))	represent	the	“chromosomal	
instability”	(CIN)	also	called	a	“suppressor”	pathway	(24).
Observation	of	sporadic	colorectal	cancers	showed	that	only	about	50%	of	tumours	
had	features	typical	for	“suppressor”	pathway.	In	14%	of	tumours	the	high	microsatellite	
instability	 (MSI-H)	phenotype	was	observed	 (25).	The	MSI-H	phenotype	 is	 typically	
observed	among	HNPCC,	and	was	described	as	another	potential	mechanism	of	tumori-
genesis	in	colorectal	cancer	called	a	“mutator”	pathway	(26)	[see	above].	Above	3%	of	
tumours	had	both	“suppressor”	and	“mutator”	characteristic,	thus	about	40%	of	sporadic	
colorectal	cancers	might	progress	through	other	molecular	mechanisms.	
The	third	proposed	pathway	of	tumorigenesis	in	colorectal	cancer	involved	transcrip-
tional	silencing	of	selected	genes,	and	it	has	been	termed	“CpG	island	methylator	phe-
notype”	(CIMP)	(27).	This	phenotype	is	different	from	age-related	(type	A)	methylation	
that	occurs	with	the	ageing.	The	mechanism	of	epigenetic	gene	silencing,	by	methylation	
of	the	particular	gene	promoter,	leads	to	lack	of	activity	of	tumour	suppressor	genes	in	
some	 cancers	 (28).	There	 is	 also	 evidence	 that	 hypermethylation	 of	 promoter	 region	
of	hMLH1 leads	to	microsatellite	instability	(MSI)	in	non-hereditary	colorectal	cancers	
(29).	It	has	been	found	that	both	alleles	of	hMLH1 were hypermethylated in five out of 
six MSI colon cancer cell lines that lacked identifiable mismatch repair gene mutations 
(30).	Increasing	attention	on	the	contribution	of	epigenetics	to	tumorigenesis	resulted	in	
discovering	other	genes,	which	silencing	by	mypermethylation	lead	to	the	loss	of	key	
regulatory	functions	(31).
Alternative	model	of	tumorigenesis	in	colorectal	cancer	suggests	that	some	tumours	
may	arise	as	a	result	of	inhibition	of	apoptosis	and	subsequent	inactivation	of	the	DNA	
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repair	system.	It	has	been	shown	that	aberrant	crypt	foci	(ACF)	(the	earliest	microscopic	
lesions	of	dysplasia)	are	precursor	lesions	of	colorectal	adenomas	and	cancer.	There	are	
data	suggesting	that	some	sporadic	colorectal	cancers	arise	as	a	result	of	k-ras	mutations	
that	lead	to	ACF	and	adenomas	without	inhibition	of	the	APC	signalling	pathway	(32).	
This model of tumorigenesis probably accounts for a significant proportion of serrated 
adenomas	(33)	and	is	termed	“serrated”	pathway.
The	 increasing	 knowledge	 on	 genetic	 changes	 in	 colorectal	 cancer	 tumorigenesis	
gives	the	opportunity	for	the	development	of	molecular	tools	for	prevention	and	early	
diagnosis.	Some	molecular	DNA-based	stool	 tests	are	under	 investigation	in	 terms	of	
their sensitivity and specificity. The main candidates for screening are single gene tests 
of	mutations	of k-ras	and	APC	and	multiple	gene	test,	which	used	a	panel	of	three	genes:	
p53, k-ras and	microsatelite	marker	BAT-26	(34,	35).	More	investigations,	however,	are	
Figure 3.2. Multiple pathways to colorectal cancer
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required	to	assess	the	real	validity	of	these	new	screening	procedures,	their	cost-effec-
tiveness	and	comparability	with	conventional	screening	tests.
risk factors
About	60%	of	colorectal	cancers	are	attributable	to	improper	dietary	habits,	the	remain-
ing	 35%	 to	 genetic	 predispositions	 and	 5%	 to	 environmental	 factors	 (36).	The	main	
risk	factors	for	colorectal	cancer	are	low	consumption	of	fruits	and	vegetables	(which	
provide dietary fiber, carotenoids and other antioxidative vitamins, isoflavons, flavo-
noids,	polyphenols,	selenium	and	folate),	high	consumption	of	red	meat,	high	amount	of	
saturated	fatty	acids,	and	alcohol,	as	well	as	low	level	of	physical	activity	(37).	Possible	
mechanisms	responsible	for	the	effect	and	available	evidence	are	described	in	chapter	4	
(Causes of colorectal cancer).
There	are	several	medical	conditions	that	have	effect	on	colorectal	cancer	risk.	Some	
of them, like the use of non-steroidal anti-inflammatory drugs and hormone replacement 
therapy	decrease	it,	while	others,	especially	certain	diseases,	may	have	the	opposite	ef-
fect	(Table	3.1).
Table 3.1. Risk factors for colorectal cancer
	Intestinal polyp(s)
	Chronic inflammatory bowel disease
♦	Ulcerative colitis
♦	Crohn’s disease
	Diabetes mellitus
	Cholecystectomy
Hereditary syndromes
	Familial adenomatous polyposis
	Gardner syndrome
	Hereditary non-polyposis colorectal cancer 
syndrome
	Oldfield syndrome
	Turcot syndrome
	Peutz-Jeghers syndrome
	Juvenille polyposis
	Cowden disease
	Bannayan-Ruvalcaba syndrome
	Li-Fraumeni syndrome
	Bloom syndrome 
Non-modifiable risk factors of colorectal cancer (CRC):
1.	 Age	–	the	risk	increases	with	the	age;	more	than	90%	of	patients	are	old	over	50	years	
at	the	time	of	CRC	diagnosis.
2.	 Family	history	of	colorectal	cancer	–	persons	with	a	history	of	colorectal	cancer	in	the	
first-degree relatives run twice as high risk of CRC, and the risk is higher if CRC was 
diagnosed in the relative aged below 60 years or if two or more first-degree relatives 
were	diagnosed	to	have	CRC.
3.	 Race	–	the	highest	CRC	risk	was	observed	among	African	Americans.
4.	 Ethnic	–	Ashkenazi	Jews	run	the	highest	CRC	risk	in	the	world	due	to	the	presence	of	
several	gene	mutations	(e.g.,	I1307K	APC	mutation).
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Signs and symptoms
In	general,	there	are	no	early	symptoms	of	the	CRC.	Table	3.2	demonstrates	a	variety	of	
symptoms	reported	by	the	patients	that	may	be	associated	with	colorectal	cancer.
Table 3.2. Symptoms in colorectal cancer
	Change in bowel habits
	Diarrhea
	Constipation
	Unfinished bowel movement feeling
	Blood in stool
	Narrower stools
	Gastrointestinal bleeding
	Abdominal discomfort
	Abdominal bloating
	Abdominal fullness
	Abdominal cramps
	Loss of appetite
	Weight loss
	Extreme tiredness
	Vomiting
	Anemia
There	are	no	pathognomonic	symptoms	as	well.	All	above	mentioned	manifestations	
may	accompany	many	other	gastrointestinal	disorders,	however,	if	any	of	these	appear,	
it	 is	necessary	 to	contact	general	practitioner	 for	physical	 examination	and	necessary	
diagnostic	procedures.
Diagnosis
Routine	diagnostic	procedures	in	colorectal	cancer	are	presented	in	Table	3.3.
Table 3.3. Diagnostic procedures in colorectal cancer (38, 39, 40, 41, 42, 43, 44)
Diagnostic procedure
Sensitivity$ 
(range) 
[in %]
Specificity$ 
(range) 
[in %]
	Digital rectal examination*
	Rectoscopy*
	Flexible sigmoidoscopy
	Colonoscopy
	Virtual colonoscopy (CT)
	Fecal occult blood test (FOBT) unrehydrated
	Fecal occult blood test (FOBT) rehydrated
	Double-contrast barium enema
	Fecal immunochemical tests
	Genetic (MSI) testing**
76
78
90 (80–95)
95 (85–95)
65-90 (58–96)
33 (20–40)
60 (40–65)
70 (60–90)
61–91
81 (73–89)
92
84
95 (90–100)
100
86-89 (81–92)
97 (95–99)
90 (85–95)
86 (80–98)
97–98
92 (90–94)
$ – for cancer
* – for rectal cancer
** – genetic testing should be considered as one part of the clinical evaluation of patients who are suspected of 
having inherited colon cancer syndromes
The final diagnosis of colorectal cancer is based on histopathological examination of 
suspected	tissue	obtained	by	biopsy.
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There	are	three	main	types	of	colorectal	cancer:
1)	 sporadic	colorectal	cancer	–	diagnosed	among	persons	without	familial	or	inherited	
predisposition,
2)	 inherited	colorectal	cancer	–	covers	any	of	inherited	cancers,	which	are	divided	into	
colorectal	cancer	with	polyps	and	without	polyps:
Without polyps
	Hereditary Non-Polyposis Colorectal Cancer 
(HNPCC)*
•	 AC-1 group A (with MMR deficiency; sho-
wed increased incidence of extracolonic 
cancers; previously Lynch II)
•	 AC-1 group B (without MMR deficiency; 
showed lower incidence of extracolonic 
cancers; previously Lynch I)
With polyps
	Familial Adenomatous Polyposis (FAP)
	Attenuated Familial Adenomatous Polyposis 
(AFAP)
	Mixed Polyposis Syndrome
	Ashkenazi I1307K colon cancer
	Hereditary Breast and Colorectal Cancer 
(HBCC; CHEK2)
	Hamartomatous Polyposis Syndrome
•	 Peutz-Jeghers syndrome
•	 Familial Juvenile Polyposis
•	 Cowden’s disease
•	 Bannayan-Ruvalcaba-Riley syndrome
* new classification proposed by Lindor et al. (45) and based on the knowledge about MMR mutations and their 
causal significance in the Lynch syndrome
3)	 familial	colon	cancer	–	recognized	when	colon	cancer	develops	too	frequently	to	be	
considered	sporadic,	but	not	in	a	pattern	characteristic	for	inherited	syndrome.
In	1991	clinical	Amsterdam	criteria	were	proposed	for	HNPCC.	Later	on,	after	the	
researchers	had	found	out	that	mutations	of	the	MMR	genes	are	causing	HNPCC,	the	
newer,	Bethesda	criteria	were	developed	that	incorporated	the	pre-existing	Amsterdam	
guidelines	(see	Table	3.4	below).
Table 3.4. Clinical criteria for Hereditary Non-Polyposis Colorectal Cancer (HNPCC) (46, 47)
Amsterdam (I) criteria:
At least three relatives with histologically confirmed colorectal cancer and all of the following:
1) one affected person is a first-degree relative of the other two affected persons
2) two successive generations affected
3) at least one of the relatives with colorectal cancer diagnosed before 50 years of age
4) Familial Adenomatous Polyposis has been excluded
Modified Amsterdam (II) criteria:
At least three relatives with histologically confirmed HNPCC-associated* cancer and all of the following:
1) one affected person is a first-degree relative of the other two affected persons
2) two successive generations affected
3) at least one of the relatives with colorectal cancer diagnosed before 50 years of age
4) Familial Adenomatous Polyposis has been excluded
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Bethesda criteria:
The Amsterdam criteria or one of the following:
1) two cases of HNPCC-associated* cancer diagnosed in one patient, including synchronous or 
metachronous cancer
2) diagnosis of colorectal cancer and a first-degree relative with HNPCC-associated* cancer and/
or colonic adenoma (one case of cancer diagnosed before 45 years of age and adenoma diag-
nosed before 40 years of age
3) colon or endometrial cancer diagnosed before 45 years of age
4) right sided colon cancer that has an undifferentiated pattern (solid-cribriform) or signet-cell histo-
pathologic characteristics diagnosed before 45 years of age
5) adenomas diagnosed before 40 years of age
* HNPCC-associated cancers include: colorectal, endometrial, stomach, ovarian, pancreas, ureter or renal pel-
vis, biliary tract, and brain (usually glioblastoma as seen in Turcot syndrome) tumours, sebaceous gland adeno-
mas and keratoacanthomas in Muir-Torre syndrome, and carcinoma of the small bowel.
Screening
It	is	well	known	that	colorectal	cancer	screening	is	effective,	improves	surveillance	and	
provides life-saving benefits. The type of screening procedure and frequency of exami-
nation	is	related	to	the	risk	of	developing	colorectal	cancer	in	the	future,	and	this	depends	
mainly	on	the	individual	genetic	predisposition.	
Risk Screening method Age to begin screening Interval
Classical FAP (48) Sigmoidoscopy1 10–12 2 years1
Attenuated FAP (48) Colonoscopy 18–20 2 years1
HNPCC2 (49) Colonoscopy 20–25 1–2 years
Familial clustering of colorec-
tal cancer without evidence of 
MSI3 (49)
Colonoscopy
45–50 or 5–10 before age 
at diagnosis of first CRC 
in family
3–5 years
≥ 2 first-degree relatives with 
colorectal cancer or adeno-
matous polyps at age < 60
Colonoscopy
40 or 10 before age at 
diagnosis of first CRC  
in family
3–5 years
First-degree relative with 
colorectal cancer or adeno-
matous polyp at age ≥ 60
FOBT
sigmoidoscopy
FOBT + sigmoidoscopy4
DCBE
Colonoscopy
40
40
40
40
40
1 year
5 years
1 and 5 years
5–10 years
10 years
Average risk
FOBT
sigmoidoscopy
FOBT + sigmoidoscopy
DCBE
Colonoscopy
50
50
50
50
50
1 year
5 years
1 and 5 years
5–10 years
10 years
FAP – familial adenomatous polyposis; HNPCC – hereditary non-polyposis colorectal cancer; MSI – microsatel-
lite instability; CRC – colorectal cancer; DCBE – double-contrast barium enema.
1 once adenomas are detected annual colonoscopy should be performed until colectomy is planned,
2 at the age 30–35 other screening methods are recommended for extracolonic localisation, like gynaecologi-
cal examination, transvaginal ultrasound, aspiration biopsy, gastroduodenoscopy, abdominal ultrasound, and if 
urinary tract cancer runs in the family also urinalysis and urine cytology,
3 Amsterdam positive families,
4 combined testing (e.g., FOBT annually and sigmoidoscopy every 5 years) is preferred over either annual FOBT 
or sigmoidoscopy every 5 years alone.
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Pathology
Over	95%	of	colorectal	 cancers	 are	adenocarcinomas.	There	are	also	other,	however,	
very	rare	cancers	observed	in	colon	and	rectum,	like	epidermoid	(1.5%),	other	than	ad-
enocarcinoma specified cancers (13%) (carcinoid, small cell carcinoma, undifferentiated 
carcinoma),	and	sarcomas	(0.1%)	(leiomyosacromas,	angiosarcomas,	lyposarcomas,	and	
fibrosarcomas) (50).
The staging of colorectal cancer is based on Duke’s classification (Fig. 3.3) modified 
later	by	Astler-Coller:
•	 Duke A – tumour penetrates into the mucosa of the bowel but not infiltrates muscula-
ris	propria,
•	 Duke	B1	–	tumour	penetrates	into	but	not	through	the	muscularis	propria,
•	 Duke	B2	–	 tumour	penetrates	 into	and	 through	the	muscularis	propria,	 there	 is	no	
pathologic	evidence	of	metastatic	cells	in	the	lymph	nodes,
•	 Duke	C1	–	tumour	penetrates	into	but	not	through	the	muscularis	propria,	but	there	is	
pathologic	evidence	of	metastatic	cells	in	the	lymph	nodes,
•	 Duke	C2	–	tumour	penetrates	into	and	through	the	muscularis	propria,	and	there	is	
pathologic	evidence	of	metastatic	cells	in	the	lymph	nodes,
•	 Duke	D	–	tumour	has	spread	beyond	the	lymph	nodes,	to	distant	organs.
Figure 3.3. The Duke’s classification of colorectal cancer
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The	American	Joint	Committee	on	Cancer	(AJCC)	introduced	the	system	classify-
ing tumours into the four (in fifth edition) and into seven (in sixth edition) stages, which 
depend	on	the	tumour	(T),	lymph	nodes	(N)	and	metastases	(M)	features:
Tumour (T) Lymph nodes (N) Metastasis (M)
T1 – tumor invades submucosa
T2 – tumor invades muscularis 
propria
T3 – tumor invades through the 
muscularis propria into the 
subserosa, or into the peri-
colic or perirectal tissues
T4 – tumor directly invades 
other organs or structures, 
and/or perforates*
N0 – no regional lymph node 
metastasis
N1 – metastasis in 1 to 3 regio-
nal lymph nodes
N2 – metastasis in 4 or more 
regional lymph nodes
M0 – no distant metastasis
M1 – Distant metastasis present
* The most likely organs to experience metastasis from colorectal cancer are the lungs and liver.
Stages as defined by the American Joint Committee on Cancer (AJCC) are as fol-
lows:
T N M
AJCC – 5th edition
I T1 or T2 N0 M0
II T3 or T4 N0 M0
III any T N1 M0
IV any T any N M1
AJCC – 6th edition
I T1 or T2 N0 M0
IIa T3 N0 M0
IIb T4 N0 M0
IIIa T1 or T2 N1 M0
IIIb T3 or T4 N1 M0
IIIc any T N2 M0
IV any T any N M1
These classifications are used to stratify patients in terms of predicted survival, to 
support	the	decision	making	on	the	most	effective	treatment,	to	prognose,	and	to	evaluate	
cancer	control	measures	(51).
Prognosis and survival
The	effectiveness	of	treatment	of	colorectal	cancer	depends	on	the	stage	of	the	disease	at	
the	time	of	diagnosis.	The	analysis	of	the	data	from	the	Surveillance,	Epidemiology	and	
End	Results	(SEER)	program,	a	large	US	cancer	registry,	from	the	year	1991	through	the	
end	of	2000	showed,	that	5-year	survival	for	patients	at	stage	I	(6-th	AJCC)	was	about	
93%,	at	stage	IIa	–	85%,	IIb	–	72%,	IIIa	–	83%,	IIIb	–	64%,	and	at	stage	IIIc	–	44%.	
The	lowest	survival	rate	was	observed	for	those	patients,	who	were	at	stage	IV.	In	that	
Jedrychowski 3.indd   27 06-06-2009   17:13:29
2 Aleksander Galas
* NOS = not otherwise specified; 1% of cases was overlapping sites
Figure 3.4. Distribution of colorectal cancer by tumour site and 5-year survival rates (in parenthesis) by 
regions (USA and Europe)
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group,	the	5-year	survival	only	slightly	exceeded	8%	(52).	The	prognosis	depends	also	
on	the	histologic	subtype	of	the	cancer.	The	worse	prognosis	was	observed	for	signet	ring	
cell	carcinomas	(5-year	survival:	36%).	Survival	rate	depends	not	only	on	stage	of	the	
cancer,	but	also	on	tumour	localization	in	the	large	intestine.	In	the	SEER	(1991–2000)	
cohort	 the	best	5-year	survival	was	observed	among	patients	with	 tumours	 located	 in	
the	sigmoid	colon	(70%).	Figure	3.4	shows	difference	between	the	USA	and	Europe	for	
colorectal	cancer	localization	and	survival	rates	(50).
It	is	worth	to	remember	that	there	are	a	lot	of	demographic,	clinical	and	social	condi-
tions, which influence the effectiveness of screening, diagnosis, treatment, and finally 
the	survival	rate.
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